CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for CCTG-Led trials has been awarded to the Princess Margaret Cancer Centre HN.10 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won.
After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung.
CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial has been closed to accrual after successfully reaching the accrual goal.
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs.
Primary publication for IND226 and MA33 QoL journal article
The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed.
About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination.
